China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science and...

China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science
and Technology Institute

HARBIN, China, June 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. (Amex: CSY) ("China Sky One" or "the Company"), a China-based
manufacturer, marketer and distributor of pharmaceutical, medicinal and
diagnostic kit products, announced today that its wholly-owned subsidiary,
Harbin First Bio-Engineering Pharmaceutical Company, was recognized as an
advanced research and development center by the Science and Technology
Institute of Heilongjiang ("the Institute") in China on June 13, 2008.
The Institute is a government supported entity that promotes the
development of high technology companies and technologically advanced
products.
The Institute will provide Harbin First Bio-Engineering Pharmaceutical Company
subsidiary with the title "Disease Kits Technology Research and Development
Center" as well as additional support and benefits, including a permanent 15%
tax on the sale of new products (the normal tax is 25%), and a subsidy of RMB
2 million for 5 years.
Harbin First Bio-Engineering Pharmaceutical Company is the only research
and development center for external use disease testing kits in Heilongjiang
Province. Disease testing kits are used for the early detection of diseases.
They require users to place a blood or urine sample on a marker and a positive
(+) or negative (-) signal will result, showing whether he or she should
consult a doctor for further testing.
"China Sky One is honored to receive this prestigious award for its
research and development ability from the Science and Technology Institute of
Heilongjiang," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky
One Medical, Inc. "We will continue to improve our technology and research and
development capabilities, and expect to establish the top research and
development and industrialization center for external use disease kits in the
world."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a China based
company engaged in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic kit products. Through its wholly-
owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
and Harbin First Bio-Engineering Company Limited the Company manufactures and
distributes over-the-counter pharmaceutical products as its primary revenue
source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain statements made in the press release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements can be identified by the use of forward-looking
terminology such as "believe," "expect," "may," "will," "should," "project,"
"plan," "seek," "intend," or "anticipate" or the negative thereof or
comparable terminology. Additional statements that are necessarily forward
looking in nature also include, without limitation, statements relating to our
research and development activities, expected revenues or sales margins,
results of recent acquisitions and our ability to increase sales and expand
our presence in the global market place, and risks or uncertainties relating
to PRC socioeconomic issues. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. The Company cannot provide any
assurance that it will be able to establish listing of its securities on any
national or regional securities exchange or market system. Actual results
could differ materially from the expectations reflected in such forward-
looking statements as a result of a variety of factors, including the
inability of the company to meet listing standards of an exchange, risks
associated with the effect of changing economic conditions in The People's
Republic of China, variations in cash flow, reliance on collaborative retail
partners both in China and throughout the world and on new product
development,
variations in new product development, risks associated with rapid
technological change, and the potential of introduced or undetected flaws and
defects in products, and other risk factors detailed in reports filed with the
Securities and Exchange Commission from time to time.
For more information, please contact:

China Sky One Medical, Inc.
Ms. Yanwei Zhang, Board Secretary
Tel: +86-451-53994069
Email: cntiandiren@yahoo.com.cn

CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Website: http://www.ccgelite.com

SOURCE China Sky One Medical, Inc.

China Sky One Medical, Inc. - Ms. Yanwei Zhang, Board Secretary,
+86-451-53994069, or cntiandiren@yahoo.com.cn; CCG Elite Investor Relations
Inc. - Mr. Crocker Coulson, President, +1-646-213-1915 (New York), or
crocker.coulson@ccgir.com